ECP 2022 Final Programme

ECP 2022 Basel At Janssen Oncology, we are precisely focused on mastering the areas where we can make the most meaningful difference . Through targeted transformation , our purpose is to take science from where it is to where it has not yet been. And with our first-in-class , gene-targeted therapies in oncology, 1,2 we are striving to provide the right treatment to the right patient , at the right time . That’s The Power of Purpose ®. 1. Janssen. Pharmaceutical Companies of Johnson & Johnson. RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Available at: https://bit.ly/3Rts7GD. Accessed: July 2022. 2. FDA approves first targeted therapy for metastatic bladder cancer. Available at: https://bit.ly/3v1Mfag. Accessed: July 2022. Products/indications mentioned in this document may not be registered in all countries. Prescribing information may vary per country. Health Care Professionals must refer to their country prescribing information. CP-331875 July 2022 Learn more about Janssen Oncology